Abstract
Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
Keywords: Heregulin, HER3 receptor, tumorigenicity, breast cancer.
Current Pharmaceutical Design
Title:Heregulin in Breast Cancer: Old Story, New Paradigm
Volume: 20 Issue: 30
Author(s): Ashwani Khurana, Anatilde Gonzalez-Guerrico and Ruth Lupu
Affiliation:
Keywords: Heregulin, HER3 receptor, tumorigenicity, breast cancer.
Abstract: Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
Export Options
About this article
Cite this article as:
Khurana Ashwani, Gonzalez-Guerrico Anatilde and Lupu Ruth, Heregulin in Breast Cancer: Old Story, New Paradigm, Current Pharmaceutical Design 2014; 20 (30) . https://dx.doi.org/10.2174/1381612819666131125151519
DOI https://dx.doi.org/10.2174/1381612819666131125151519 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Inhibition of AKT in Pancreatic Cancer
Current Cancer Therapy Reviews Drugs and their Interactions
Current Drug Discovery Technologies The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry The Food-gut Human Axis: The Effects of Diet on Gut Microbiota and Metabolome
Current Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry Epigenetic Regulation and Promising Therapies in Colorectal Cancer
Current Molecular Pharmacology Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) The Dual Role of Nitric Oxide in Glioma
Current Pharmaceutical Design Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Editorial [Hot Topic: Environmental Impacts on Enzymes Involved in Drug and Steroid Metabolism Guest Editor: R.H. Waring ]
Current Drug Metabolism Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Flow Shear Induced Changes in Membrane Fluidity: Dependence on Cell- Substrate Adhesion Strength
Current Analytical Chemistry Perspectives of Quality by Design Approach in Nanomedicines Development
Current Nanomedicine Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
Current Medicinal Chemistry Comparative Study of Encoder-decoder-based Convolutional Neural Networks in Cartilage Delineation from Knee Magnetic Resonance Images
Current Medical Imaging